TRAT1 and viral infectious disease: If lipid rafts are indeed selectively implicated in maladaptive TRIM and contribute to persistent low-grade inflammation, this opens the possibility of leveraging “lipid raft therapy” (115) to mitigate inflammation and address the metabolic and neurological comorbidities associated with viral infections.